Generate a tailored SOP for Dr. Fiona Ducotterd. Improve your application with a focused, well-structured draft.
Fiona Ducotterd is the Chief Scientific Officer at University College London’s Drug Discovery Institute, specializing in neuromuscular diseases. She joined UCL in November 2022 after a notable career in the pharmaceutical and biotechnology industries, including roles at Merck Sharp Dohme, GSK, and Vertex Pharmaceuticals. Fiona is driven by a personal connection to Alzheimer’s disease, having observed its effects on her family. She is dedicated to advancing drug discovery research, focusing on the development of new medicines for neurodegenerative diseases. Fiona holds a BSc in Molecular Biology from the University of Edinburgh and a PhD in Neuroscience from the University of Newcastle upon Tyne. Additionally, she completed a postdoctoral fellowship at the Okinawa Institute of Science and Technology in Japan. Throughout her career, she has led numerous research projects and has extensive experience managing international research teams and collaborations in the field of neurology and therapeutic innovation. Fiona also serves on several committees, including the Society for Neuroscience Finance Committee and the Neuroscience Scholars Program. She is committed to mentoring young scientists, especially those from underrepresented backgrounds in the industry.
University College London • London, United Kingdom
Leading drug discovery research initiatives focused on neuromuscular diseases.
Vertex Pharmaceuticals • Boston, United States
Managed strategic partnerships and alliances in drug development.
Eisai • Andover, United States
Oversaw external partnerships and research collaborations.
Eisai • Andover, United States
Conducted research in neurology and drug discovery.
Okinawa Institute of Science and Technology • Okinawa, Japan
Focused on brain mechanisms and behavior.